CRMI (08158) announced that on January 2, 2026, China Regen (Hong Kong) Investment Limited (a wholly-owned subsidiary of the Company) entered into a sale and purchase agreement with China Star Entertainment (BVI) Limited (China Star) (a wholly-owned subsidiary of China Star Group Limited, a company listed on the Main Board of The Stock Exchange of Hong Kong Limited (Stock Code: 0326)). Pursuant to the agreement, China Regen (Hong Kong) agreed to acquire a 55% equity interest in Kangmeizan Biotech Development Limited (formerly known as Hong Kong Deboni Culture Media Limited) (a wholly-owned subsidiary of China Star) for a consideration of HK$5,500. Following the completion of the acquisition, China Regen (Hong Kong) and China Star will hold 55% and 45% of the equity in Kangmeizan, respectively, with the transaction under the sale and purchase agreement concluding simultaneously. To govern the rights and obligations of China Regen (Hong Kong) and China Star as shareholders of Kangmeizan, a shareholders' agreement was executed by China Regen (Hong Kong), China Star, and Kangmeizan upon completion of the sale and purchase agreement. It was further confirmed that Kangmeizan will operate as an investment holding company, making investments in the Macao Special Administrative Region of the People's Republic of China and collaborating with other strategic investors to operate clinic businesses in Macao. This strategic partnership is designed to further leverage the respective professional capabilities and resource advantages of each party. On one hand, the Group can utilize China Star's resources and business connections in Macao to enhance its competitive edge in the region. On the other hand, Kangmeizan can benefit from the Group's industry resources and extensive experience in aesthetic medicine, beauty services, and medical services to achieve synergies. The strategic cooperation represents a significant milestone for the Group's expansion into the new market of Macao. The parties involved will not only realize synergistic growth for their respective businesses through this collaboration but will also unlock new market opportunities and commercial value for their companies.